Deferasirox - An oral agent for chronic iron overload

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1110-1117

  VanOrden, Heidi E ^a   Hagemann, Tracy M ^b  

^a CHILDREN S MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

thalassemia; Chronic iron overload; Deferasirox; Exjade; ICL670

Indexed keywords

ANTACID AGENT; ASCORBIC ACID; DEFERASIROX; DEFEROXAMINE; DIGOXIN; HYDROXYUREA; IRON; IRON CHELATING AGENT;

ABDOMINAL PAIN; ANEMIA; BETA THALASSEMIA; BLOOD TOXICITY; CARDIOTOXICITY; CATARACT; CHRONIC DISEASE; CHRONIC IRON OVERLOAD; CLINICAL TRIAL; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; CREATININE BLOOD LEVEL INCREASE; DEVICE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEARING LOSS; HUMAN; INFORMATION RETRIEVAL; INTERNATIONAL PHARMACEUTICAL ABSTRACTS; INTRAOCULAR HYPERTENSION; IRON CHELATION; IRON LIVER LEVEL; IRON OVERLOAD; LIVER LEVEL; LIVER TOXICITY; MEDLINE; NAUSEA; NEPHROTOXICITY; NON INVASIVE MEASUREMENT; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; RASH; REFERENCE DATABASE; REVIEW; SUPERCONDUCTION QUANTUM INTERFERENCE DEVICE; TABLET; TOXIC HEPATITIS; VOMITING;

BENZOIC ACIDS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; TRIAZOLES;

EID: 33745101113     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G566     Document Type: Review

References (26)

1. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
2. Kushner JP, Porter JP, Oliveri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program) 2001:47-61.
3. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004;104:34-9.
4. deVirgiliis S, Sanna G, Cornacchia G, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassemia. Arch Dis Child 1980;55:43-5.
5. Lo L, Singer ST. Thalassemia: current approach to an old disease. Pediatr Clin North Am 2002;49:1165-91.
6. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of beta-thalassemia. Best Pract Res Clin Haematol 2002;15:329-68.
7. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
8. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
9. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.
10. Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of 4-(3,5-bis-(hydroxyl-phenyl)-1,2,4)triazol-1- yl)-benzoic acid for the treatment of chronic iron overload requiring chelation therapy. London: European Medicines Agency, 2003 Jan 8.
11. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509:185-203.
12. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
13. National Horizon Scanning Center. Deferasirox (ICL670) for iron overload. Jan 2005. www.pcpoh.bham.ac.uk/publichealth/horizon (accessed 2005 Jun 20).
14. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003;43:565-72.
15. Package insert. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals, November 2005.
16. Barton JC. Deferasirox (Novartis). Curr Opin Investig Drugs 2005;6:327-35.
17. Hershko C, Konijin AM, Nick HP, et al. ICL670: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001;97:1115-22.
18. Sergejew T, Forgiarini P, Schnebli HP. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 2000;110:985-92.
19. Cappellini M. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005;18:289-98.
20. Novartis media release. Novartis files Exjade new drug applications for treatment of chronic iron overload due to blood transfusions. May 3, 2005. www.novartis.com (accessed 2005 May 14).
21. Piga A, Galanello R, Cappellini MD, et al. Phase II study of oral chelator ICL670 in thalassemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy (abstract). Blood 2002;100:5a.
22. Porter J, Vichinsky E, Rose C, et al. A Phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various tranfusion-dependent anemias and iron overload (abstract). Blood 2004;104:3193.
23. Gattermann N, Cazzola M, Greenberg P, et al. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload (abstract). Leuk Res 2005;29(suppl 1):S67.
24. Cappellini M, Bejaoui M, Perrotta S, et al. Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis (abstract). Blood 2004;104:3619.
25. Food and Drug Administration. NDA 21-882. Exjade Advisory Committee Summary. www.fda.org/ohrms/dockets/ac/05/briefing/2005-4177B1_02_a. pdf (accessed 2006 Jan 24).
26. Piga A, Galanello R, Foschini ML, et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade): results of a Phase II study in pediatric patients with β-thalassemia major (abstract). Blood 2004;104:3614.